Compare · DHAI vs RMD
DHAI vs RMD
Side-by-side comparison of DIH Holdings US Inc. (DHAI) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DHAI and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD carries a market cap of $34.07B.
- Over the past year, DHAI is down 76.3% and RMD is down 11.9% - RMD leads by 64.3 points.
- RMD has hit the wire 9 times in the past 4 weeks while DHAI has been quiet.
- RMD has more recent analyst coverage (25 ratings vs 0 for DHAI).
- Company
- DIH Holdings US Inc.
- ResMed Inc.
- Price
- $0.79-56.51%
- $239.08-1.35%
- Market cap
- -
- $34.07B
- 1M return
- +0.00%
- +4.60%
- 1Y return
- -76.27%
- -11.93%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 0
- 9
- Recent ratings
- 0
- 25
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest DHAI
- DIH Holdings US Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- DIH Holdings US Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Unregistered Sales of Equity Securities
- DIH Holdings US Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- SEC Form 10-K filed by DIH Holdings US Inc.
- DIH Holdings US Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- DIH Announces Fiscal 2025 Fourth Quarter and Fiscal Year End Financial Results
- DIH Holdings US Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- DIH Holding US, Inc. Announces Reverse Stock Split of its Series A Common Stock
- DIH Holdings US Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- DIH Holdings US Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits
Latest RMD
- SEC Form 4 filed by ResMed Inc.
- SEC Form DEFA14A filed by ResMed Inc.
- SEC Form DEF 14A filed by ResMed Inc.
- Amendment: SEC Form 4 filed by Chairman and CEO Farrell Michael J.
- Chief Product Officer Leong Justin was granted 6,461 units of ResMed Common Stock, increasing direct ownership by 22% to 35,489 units (SEC Form 4)
- Global General Counsel Rider Michael J was granted 3,230 units of ResMed Common Stock, increasing direct ownership by 34% to 12,718 units (SEC Form 4)
- Chairman and CEO Farrell Michael J. was granted 13,547 units of ResMed Common Stock, increasing direct ownership by 3% to 479,803 units (SEC Form 4)
- Chief Financial Officer Bloomer Aaron was granted 9,072 units of ResMed Common Stock (SEC Form 4)
- Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026
- ResMed upgraded by RBC Capital Mkts with a new price target